Fri, January 17, 2025
Thu, January 16, 2025
[ Thu, Jan 16th ] - Forbes
Gold Price Today
Wed, January 15, 2025
Tue, January 14, 2025
Mon, January 13, 2025
Sun, January 12, 2025
Sat, January 11, 2025
Fri, January 10, 2025
Thu, January 9, 2025
[ Thu, Jan 09th ] - Kiplinger
The Best Bank ETFs to Buy

Jim Cramer on Arbutus Biopharma Corporation (ABUS): 'It Loses Money'


//stocks-investing.news-articles.net/content/202 .. s-biopharma-corporation-abus-it-loses-money.html
Published in Stocks and Investing on by MSN   Print publication without navigation

We recently compiled a list of the Jim Cramer's Lightning Round: 7 Stocks Under the Spotlight. In this article, we are going to take a look at where Arbutus Biopharma Corporation (NASDAQ:ABUS) stands against the other stocks featured in Jim Cramer's Lightning Round.

Jim Cramer, in a recent segment, discussed Arbutus Biopharma Corporation (ABUS), a company focused on developing treatments for Hepatitis B and other coronaviruses. He highlighted that despite Arbutus's innovative approach and promising pipeline, the company is currently not profitable. Cramer pointed out that Arbutus has been incurring significant losses, which is a concern for investors looking for immediate returns. He emphasized the high-risk nature of investing in biotech firms like Arbutus, where the potential for future earnings is high, but so is the risk of failure in drug development. This analysis reflects Cramer's cautious stance on investing in companies that are not yet generating profits, especially in the volatile biotech sector.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/top-stocks/jim-cramer-on-arbutus-biopharma-corporation-abus-it-loses-money/ar-AA1xjNei ]

Publication Contributing Sources